title: Lipoxin A4 attenuates acute rejection via shifting TH1/TH2 cytokine balance in rat liver transplantation.
abstract: OBJECTIVE
  To study the role of lipoxin A4 (LXA4) in rat liver transplant rejection.
  
  
  METHODS
  An acute rejection model of liver transplantation was established in inbred rats DA to LEW that were randomly divided into a control group and a LXA4 group. Liver morphologic changes were examined using hematoxylin/eosin staining. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were quantified to measure liver injury. Intragraft mRNA and protein expressions of interferon (IFN)-γ interleukin and (IL)-10 were detected by real-time polymerase chain reaction and Western blots, respectively. The serum levels of IFN-γ and IL-10 were assayed by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  LXA4 treatment improved hepatic tissue injury as indicated by morphologic analysis. Serum ALT and AST levels were significantly decreased at day 7 post-transplantation (P < .05). Concurrently, expression of IFN-γ was downregulated (P < .05) and secretion of IL-10 was enhanced (P < .05).
  
  
  CONCLUSIONS
  LXA4 attenuated acute rejection with a parallel shift from Th1 to Th2 responses in rat liver transplantation.
authors.affiliation: Chongqing Ninth People's Hospital, Chongqing, China.
authors.forename: W
authors.initials: W
authors.lastname: Liao
authors.forename: F
authors.initials: F
authors.lastname: Zeng
authors.forename: K
authors.initials: K
authors.lastname: Kang
authors.forename: Y
authors.initials: Y
authors.lastname: Qi
authors.forename: L
authors.initials: L
authors.lastname: Yao
authors.forename: H
authors.initials: H
authors.lastname: Yang
authors.forename: L
authors.initials: L
authors.lastname: Ling
authors.forename: N
authors.initials: N
authors.lastname: Wu
authors.forename: D
authors.initials: D
authors.lastname: Wu
mesh_terms: D000208:Acute Disease; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood* / Q000235:genetics; D004195:Disease Models, Animal; D006084:Graft Rejection / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D044045:Lipoxins / Q000494:pharmacology*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects* / Q000276:immunology
chemical_list: D015415:Biomarkers; D016207:Cytokines; D007166:Immunosuppressive Agents; D044045:Lipoxins; D012333:RNA, Messenger; C040527:lipoxin A4; D016753:Interleukin-10; D007371:Interferon-gamma; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase